Group I and group II metabotropic glutamate receptors: Role in pathophysiology and treatment of major depressive disorder

Metabotropic Glutamate Receptors: Molecular Mechanisms, Role in Neurological Disorders and Pharmacological Effects

Volumn , Issue , 2014, Pages 135-150

  Holly, Elizabeth N ^a   LaCrosse, Amber L ^b   Hillhouse, Todd M ^c  

^a TUFTS UNIVERSITY   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Antidepressant; Glutamate; Major depressive disorder; Metabotropic glutamate receptors; MGluR1; MGluR2 3; MGluR5

Indexed keywords

EID: 84925644280     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (83)

1. Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., Wang, P. S. (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289: 3095-3105.
2. Belmaker, R. H. (2008) The future of depression psychopharmacology. CNS Spectr. 13: 682-687.
3. Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., Wittchen, H. U. (2012) Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int. J. Methods Psychiatr. Res. 21:169-184.
4. Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jonsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., Fratiglioni, L., Jennum, P., Lieb, R., Maercker, A., van Os, J., Preisig, M., Salvador-Carulla, L., Simon, R., Steinhausen, H. C. (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 21:655-679.
5. Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., Corey-Lisle, P. K. (2003) The economic burden of depression in the United States: how did it change between 1990 and 2000? J. Clin. Psychiatry 64:1465-1475.
6. Andlin-Sobocki, P., Rossler, W. (2005) Cost of psychotic disorders in Europe. Eur. J. Neurol. 12 Suppl. 1:74-77.
7. Murray, C. J., Lopez, A. D. (1996) Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 274:740-743.
8. Uher, R., Mors, O., Rietschel, M., Rajewska-Rager, A., Petrovic, A., Zobel, A., Henigsberg, N., Mendlewicz, J., Aitchison, K. J., Farmer, A., McGuffin, P. (2011) Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. J. Clin. Psychiatry 72: 1478-1484.
9. Hashimoto, K. (2011) The role of glutamate on the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 35:1558-1568.
10. Altamura, C. A., Mauri, M. C., Ferrara, A., Moro, A. R., D'Andrea, G., Zamberlan, F. (1993) Plasma and platelet excitatory amino acids in psychiatric disorders. Am. J. Psychiatry 150:1731-1733.
11. Kim, J. S., Schmid-Burgk, W., Claus, D., Kornhuber, H. H. (1982) Increased serum glutamate in depressed patients. Arch. Psychiatr. Nervenkr. 232:299-304.
12. Levine, J., Panchalingam, K., Rapoport, A., Gershon, S., McClure, R. J., Pettegrew, J. W. (2000) Increased cerebrospinal fluid glutamine levels in depressed patients. Biol. Psychiatry 47:586-593.
13. Mauri, M. C., Ferrara, A., Boscati, L., Bravin, S., Zamberlan, F., Alecci, M., Invernizzi, G. (1998) Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 37:124-129.
14. Mitani, H., Shirayama, Y., Yamada, T., Maeda, K., Ashby, C. R., Jr., Kawahara, R. (2006) Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 30:1155-1158.
15. Kucukibrahimoglu, E., Saygin, M. Z., Caliskan, M., Kaplan, O. K., Unsal, C., Goren, M. Z. (2009) The change in plasma GABA, glutamine and glutamate levels in fluoxetine-or S-citalopram-treated female patients with major depression. Eur. J. Clin. Pharmacol. 65:571-577.
16. Garakani, A., Martinez, J. M., Yehuda, R., Gorman, J. M. (2013) Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment. J. Affect Disord. 146:262-265.
17. Maes, M., Verkerk, R., Vandoolaeghe, E., Lin, A., Scharpe, S. (1998) Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr. Scand. 97:302-308.
18. Hashimoto, K., Sawa, A., Iyo, M. (2007) Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry 62:1310-1316.
19. Choudary, P. V., Molnar, M., Evans, S. J., Tomita, H., Li, J. Z., Vawter, M. P., Myers, R. M., Bunney, W. E., Jr., Akil, H., Watson, S. J., Jones, E. G. (2005) Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc. Natl. Acad. Sci. US 102:15653-15658.
20. Bernard, R., Kerman, I. A., Thompson, R. C., Jones, E. G., Bunney, W. E., Barchas, J. D., Schatzberg, A. F., Myers, R. M., Akil, H., Watson, S. J. (2011) Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol. Psychiatry 16:634-646.
21. Altamura, C., Maes, M., Dai, J., Meltzer, H. Y. (1995) Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur. Neuropsychopharmacol. 5 Suppl.:71-75.
22. Frye, M. A., Tsai, G. E., Huggins, T., Coyle, J. T., Post, R. M. (2007) Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol. Psychiatry 61:162-166.
23. Sanacora, G., Gueorguieva, R., Epperson, C. N., Wu, Y. T., Appel, M., Rothman, D. L., Krystal, J. H., Mason, G. F. (2004) Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry 61:705-713.
24. Auer, D. P., Putz, B., Kraft, E., Lipinski, B., Schill, J., Holsboer, F. (2000) Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol. Psychiatry 47:305-313.
25. Pfleiderer, B., Michael, N., Erfurth, A., Ohrmann, P., Hohmann, U., Wolgast, M., Fiebich, M., Arolt, V., Heindel, W. (2003) Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res. 122:185-192.
26. Michael, N., Erfurth, A., Ohrmann, P., Arolt, V., Heindel, W., Pfleiderer, B. (2003) Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression. Neuropsychopharmacology 28:720-725.
27. Block, W., Traber, F., von Widdern, O., Metten, M., Schild, H., Maier, W., Zobel, A., Jessen, F. (2009) Proton MR spectroscopy of the hippocampus at 3T in patients with unipolar major depressive disorder: correlates and predictors of treatment response. Int. J. Neuropsychopharmacol. 12:415-422.
28. Michael, N., Erfurth, A., Ohrmann, P., Arolt, V., Heindel, W., Pfleiderer, B. (2003) Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. Psychol. Med. 33:1277-1284.
29. Hasler, G., van der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., Drevets, W. C. (2007) Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 64:193-200.
30. Mirza, Y., Tang, J., Russell, A., Banerjee, S. P., Bhandari, R., Ivey, J., Rose, M., Moore, G. J., Rosenberg, D. R. (2004) Reduced anterior cingulate cortex glutamatergic concentrations in childhood major depression. J. Am. Acad. Child Adolesc. Psychiatry 43:341-348.
31. 11C]ABP688 PET and postmortem study. Am. J. Psychiatry 168:727-734.
32. Feyissa, A. M., Woolverton, W. L., Miguel-Hidalgo, J. J., Wang, Z., Kyle, P. B., Hasler, G., Stockmeier, C. A., Iyo, A. H., Karolewicz, B. (2010) Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 34:279-283.
33. Beneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E., Meador-Woodruff, J. H. (2007) Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 32:1888-1902.
34. Feyissa, A. M., Chandran, A., Stockmeier, C. A., Karolewicz, B. (2009) Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 33:70-75.
35. Nudmamud-Thanoi, S., Reynolds, G. P. (2004) The NR1 subunit of the glutamate/ NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci. Lett. 372:173-177.
36. Pin, J. P., Duvoisin, R. (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34:1-26.
37. Schoepp, D. D., Conn, P. J. (2002) Metabotropic glutamate receptors. Pharmacol. Biochem. Behav. 74:255-256.
38. Schoepp, D. D., Conn, P. J. (1993) Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol. Sci. 14:13-20.
39. Stefani, M. R., Moghaddam, B. (2010) Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade. Eur. J. Pharmacol. 639:26-32.
40. Cunningham, M. D., Ferkany, J. W., Enna, S. J. (1994) Excitatory amino acid receptors: a gallery of new targets for pharmacological intervention. Life Sci. 54:135-148.
41. Hollmann, M., Heinemann, S. (1994) Cloned glutamate receptors. Annu. Rev. Neurosci. 17: 31-108.
42. Ozawa, S., Kamiya, H., Tsuzuki, K. (1998) Glutamate receptors in the mammalian central nervous system. Prog. Neurobiol. 54:581-618.
43. Lau, C. G., Zukin, R. S. (2007) NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat. Rev. Neurosci. 8:413-426.
44. Albensi, B. C. (2007) The NMDA receptor/ion channel complex: a drug target for modulating synaptic plasticity and excitotoxicity. Curr. Pharm. Des. 13:3185-3194.
45. Hardingham, G. E., Bading, H. (2003) The Yin and Yang of NMDA receptor signalling. Trends Neurosci. 26:81-89.
46. Lu, W., Man, H., Ju, W., Trimble, W. S., MacDonald, J. F., Wang, Y. T. (2001) Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons. Neuron 29:243-254.
47. Niswender, C. M., Conn, P. J. (2010) Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 50:295-322.
48. Cryan, J. F., Slattery, D. A. (2007) Animal models of mood disorders: Recent developments. Curr. Opin. Psychiatry 20:1-7.
49. Wieronska, J. M., Branski, P., Szewczyk, B., Palucha, A., Papp, M., Gruca, P., Moryl, E., Pilc, A. (2001) Changes in the expression of metabotropic glutamate receptor 5 (mGluR5) in the rat hippocampus in an animal model of depression. Pol. J. Pharmacol. 53: 659-662.
50. Morley-Fletcher, S., Mairesse, J., Soumier, A., Banasr, M., Fagioli, F., Gabriel, C., Mocaer, E., Daszuta, A., McEwen, B., Nicoletti, F., Maccari, S. (2011) Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats. Psychopharmacology (Berl.) 217:301-313.
51. Iyo, A. H., Feyissa, A. M., Chandran, A., Austin, M. C., Regunathan, S., Karolewicz, B. (2010) Chronic corticosterone administration down-regulates metabotropic glutamate receptor 5 protein expression in the rat hippocampus. Neuroscience 169: 1567-1574.
52. Wieronska, J. M., Legutko, B., Dudys, D., Pilc, A. (2008) Olfactory bulbectomy and amitriptyline treatment influences mGlu receptors expression in the mouse brain hippocampus. Pharmacol. Rep. 60:844-855.
53. Kovacevic, T., Skelin, I., Minuzzi, L., Rosa-Neto, P., Diksic, M. (2012) Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study. Brain Res. Bull. 87:406-412.
54. Matrisciano, F., Caruso, A., Orlando, R., Marchiafava, M., Bruno, V., Battaglia, G., Gruber, S. H., Melchiorri, D., Tatarelli, R., Girardi, P., Mathe, A. A., Nicoletti, F. (2008) Defective group-II metaboropic glutamate receptors in the hippocampus of spontaneously depressed rats. Neuropharmacology 55:525-531.
55. Matrisciano, F., Storto, M., Ngomba, R. T., Cappuccio, I., Caricasole, A., Scaccianoce, S., Riozzi, B., Melchiorri, D., Nicoletti, F. (2002) Imipramine treatment up-regulates the expression and function of mGlu2/3 metabotropic glutamate receptors in the rat hippocampus. Neuropharmacology 42:1008-1015.
56. Bajkowska, M., Branski, P., Smialowska, M., Pilc, A. (1999) Effect of chronic antidepressant or electroconvulsive shock treatment on mGluR1a immunoreactivity expression in the rat hippocampus. Pol. J. Pharmacol. 51:539-541.
57. Smialowska, M., Szewczyk, B., Branski, P., Wieronska, J. M., Palucha, A., Bajkowska, M., Pilc, A. (2002) Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus. Neuropharmacology 42:1016-1023.
58. Zahorodna, A., Bijak, M. (1999) An antidepressant-induced decrease in the responsiveness of hippocampal neurons to group I metabotropic glutamate receptor activation. Eur. J. Pharmacol. 386:173-179.
59. Palucha, A., Branski, P., Klak, K., Sowa, M. (2007) Chronic imipramine treatment reduces inhibitory properties of group II mGlu receptors without affecting their density or affinity. Pharmacol. Rep. 59:525-530.
60. Belozertseva, I. V., Kos, T., Popik, P., Danysz, W., Bespalov, A. Y. (2007) Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur. Neuropsychopharmacol. 17:172-179.
61. Molina-Hernandez, M., Tellez-Alcantara, N. P., Perez-Garcia, J., Olivera-Lopez, J. I., Jaramillo-Jaimes, M. T. (2008) Desipramine or glutamate antagonists synergized the antidepressant-like actions of intra-nucleus accumbens infusions of minocycline in male Wistar rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 32:1660-1666.
62. Molina-Hernandez, M., Tellez-Alcantara, N. P., Perez-Garcia, J., Olivera-Lopez, J. I., Jaramillo-Jaimes, M. T. (2008) Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog. Neuropsychopharmacol. Biol. Psychiatry 32: 380-386.
63. Smolders, I., Clinckers, R., Meurs, A., De Bundel, D., Portelli, J., Ebinger, G., Michotte, Y. (2008) Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant-anticonvulsant action. Neuropharmacology 54:1017-1028.
64. Tatarczynska, E., Klodzinska, A., Chojnacka-Wojcik, E., Palucha, A., Gasparini, F., Kuhn, R., Pilc, A. (2001) Potential anxiolytic-and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br. J. Pharmacol. 132:1423-1430.
65. Li, X., Need, A. B., Baez, M., Witkin, J. M. (2006) Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J. Pharmacol. Exp. Ther. 319:254-259.
66. Pilc, A., Klodzinska, A., Branski, P., Nowak, G., Palucha, A., Szewczyk, B., Tatarczynska, E., Chojnacka-Wojcik, E., Wieronska, J. M. (2002) Multiple MPEP administrations evoke anxiolytic-and antidepressant-like effects in rats. Neuropharmacology 43:181-187.
67. Wieronska, J. M., Szewczyk, B., Branski, P., Palucha, A., Pilc, A. (2002) Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids 23:213-216.
68. Liu, C. Y., Jiang, X. X., Zhu, Y. H., Wei, D. N. (2012) Metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine produces antidepressant effects in rats: role of brain-derived neurotrophic factor. Neuroscience 223:219-224.
69. Palucha, A., Branski, P., Szewczyk, B., Wieronska, J. M., Klak, K., Pilc, A. (2005) Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol. Biochem. Behav. 81:901-906.
70. Palucha-Poniewiera, A., Pilc, A. (2012) Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test. Prog. Neuropsychopharmacol. Biol. Psychiatry 39:102-106.
71. Hughes, Z. A., Neal, S. J., Smith, D. L., Sukoff Rizzo, S. J., Pulicicchio, C. M., Lotarski, S., Lu, S., Dwyer, J. M., Brennan, J., Olsen, M., Bender, C. N., Kouranova, E., Andree, T. H., Harrison, J. E., Whiteside, G. T., Springer, D., O'Neil, S. V., Leonard, S. K., Schechter, L. E., Dunlop, J., Rosenzweig-Lipson, S., Ring, R. H. (2013) Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression. Neuropharmacology 66: 202-214.
72. Porter, R. H., Jaeschke, G., Spooren, W., Ballard, T. M., Buttelmann, B., Kolczewski, S., Peters, J. U., Prinssen, E., Wichmann, J., Vieira, E., Muhlemann, A., Gatti, S., Mutel, V., Malherbe, P. (2005) Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther. 315:711-721.
73. Pecknold, J. C., McClure, D. J., Appeltauer, L., Wrzesinski, L., Allan, T. (1982) Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J. Clin. Psychopharmacol. 2:129-133.
74. Ago, Y., Yano, K., Araki, R., Hiramatsu, N., Kita, Y., Kawasaki, T., Onoe, H., Chaki, S., Nakazato, A., Hashimoto, H., Baba, A., Takuma, K., Matsuda, T. (2013) Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice. Neuropharmacology 65:29-38.
75. Koike, H., Iijima, M., Chaki, S. (2013) Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats. Pharmacol. Biochem. Behav. 107:20-23.
76. Palucha-Poniewiera, A., Wieronska, J. M., Branski, P., Stachowicz, K., Chaki, S., Pilc, A. (2010) On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039. Psychopharmacology (Berl.) 212:523-535.
77. Bespalov, A. Y., van Gaalen, M. M., Sukhotina, I. A., Wicke, K., Mezler, M., Schoemaker, H., Gross, G. (2008) Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression. Eur. J. Pharmacol. 592:96-102.
78. Chaki, S., Yoshikawa, R., Hirota, S., Shimazaki, T., Maeda, M., Kawashima, N., Yoshimizu, T., Yasuhara, A., Sakagami, K., Okuyama, S., Nakanishi, S., Nakazato, A. (2004) MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 46:457-467.
79. Koike, H., Fukumoto, K., Iijima, M., Chaki, S. (2013) Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression. Behav. Brain Res. 238:48-52.
80. Campo, B., Kalinichev, M., Lambeng, N., El Yacoubi, M., Royer-Urios, I., Schneider, M., Legrand, C., Parron, D., Girard, F., Bessif, A., Poli, S., Vaugeois, J. M., Le Poul, E., Celanire, S. (2011) Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression. J. Neurogenet. 25:152-166.
81. Karasawa, J., Shimazaki, T., Kawashima, N., Chaki, S. (2005) AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res. 1042:92-98.
82. Yoshimiz, T., Shimazaki, T., Ito, A., Chaki, S. (2006) An mGluR2/3 antagonist, MGS 0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl.) 186:587-593.
83. Koike, H., Iijima, M., Chaki, S. (2011) Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists. Neuropharmacology 61:1419-1423.